Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston expands endoscopy offerings:

This article was originally published in Clinica

Executive Summary

Boston Scientific has bought a range of new endoscopic stent technologies, designed to treat gastrointestinal and airway obstructions, from Teleflex Medical subsidiary Willy Rusch. Financial details of the agreement were not disclosed. The acquired portfolio includes the Polyflex line of oesophageal and airway stents - currently distributed in the US by Boston Scientific under a previous agreement with Rusch - as well as the Y Dynamic tracheo-bronchial stent. Rusch will continue to distribute these products in Europe through to the end of 2005. Patients with oesophageal obstructions have difficulty eating and swallowing and could also suffer life-threatening interferences to their normal breathing. Endoscopic stenting is a less-invasive procedure in which a stent is inserted through an endoscope into the oesophagus, trachea or bronchial tubes to maintain the natural opening.

You may also be interested in...



EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

Topics

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel